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Living with a Spinal Cord Stimulator
Teresita DeVera, MSN, CRNP; Carol Blyzniuk, BSN, RN
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA

Research has shown that approximately one in three Americans suffer from chronic
pain, with an annual cost of $560 to $635 billion from associated healthcare costs and
lost productivity (Cruz et al, 2015). Historically, physicians have attempted to manage
pain by using opioid-based analgesics which include medications like oxycodone and
hydrocodone. Patients commonly report that pain medication becomes less effective
over time, even with dose escalations and polypharmacy. Furthermore, the consequences of long-term opioid use are numerous, including over 16,000 related deaths
annually. This has driven more pain management physicians to seek alternative treatment
modalities, such as spinal cord stimulation (SCS). SCS is an invasive therapy used to
provide pain relief for multiple types of chronic pain diagnoses when conservative and
medical therapies fail.
Spinal cord stimulation is achieved by the introduction of electrical current to the painful
area providing a more pleasant sensation, replacing the painful sensation; this is done
by introducing a thin flexible electrode into the epidural space, which will then be used
to stimulate specific targets to treat a variety of pain disorders. SCS is the number one
indication in the treatment of chronic pain despite having spinal surgery, also known as
“failed back surgery syndrome” (FBSS). Prospective randomized studies in patients who
are candidates for a second spine surgery have shown to do better with SCS with pain
reduction, health care utilization, and crossover to additional therapies and long-term
costs (Deer, 2010). SCS is also used to manage pain from chronic regional pain syndrome
(CRPS), ischemic limb pain, neuropathy, and cervical or lumbar persistent radiculopathy.
The use of neuromodulation for pain relief is among the fastest growing areas of medicine, involving many diverse specialties and impacting thousands of patients with various
ailments. Historically, electricity, whether as a torpedo fish or man-made electrotherapy,
has been used to try and cure these ailments. The modern era of neuromodulation
began in the early 1960s, first with deep brain stimulation soon followed by spinal cord
stimulation. In 1965, Melzack and Wall proposed the “gate theory” which postulated
that pain perception involves a gate that can be opened or closed depending on the
balance between firing of small and large neural fibers (Gildenberg, 2006). This concept
was tested and eventually led to the development of the first implantable stimulator in
1967, which was used to treat chronic pain with peripheral nerve stimulation. However,
the Gate Theory has not been fully adequate in explaining the full complexity of SCS
in neuromodulation.
SCS, as well as other implantable devices in neuromodulation, have made great advances
in technology over the past 4 decades. The leads have evolved from monopolar stimulation to multi-contact lead arrays. Programming SCS has become more creative, from
simple monopolar fields to complex programming options to cover multiple painful
areas. The generators have evolved from large and non-rechargeable for limb pain or
cumbersome radiofrequency devices with an external power sources required if you
had back and limb pain to smaller internal generators that can be recharged. Patients
have greater freedom to place the generator in different areas of the body, such as the
buttock, chest wall, or axilla. More recently, patients now have the option to choose
devices that are MRI-compatible with certain manufacturer restrictions.
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Conventional SCS (or tonic stimulation)
creates a paresthesia sensation overlying
the patient’s area of pain. More recently,
SCS advancements now include highfrequency stimulation (HF10), burst
stimulation, and dorsal root ganglion
(DRG) stimulation. This evolution has led
to greater pain relief and better patient
reported outcomes. There are many
benefits in choosing one form of therapy
over the other; however, the goal is to
choose the system that best addresses the
patient’s needs and will lead to a favorable
outcome. From a patient’s standpoint, the
therapy should provide the best option
of reducing pain and improving quality
of life.
The SCS device consists of electrode
leads, extension cable, a pulse generator,
and a programmer. The leads can be
percutaneous, paddle, or a hybrid of
both. Percutaneous leads, placed by a
pain physician, neurosurgeon or orthopedic surgeon, are introduced into the
epidural space via a needle under fluoroscopic guidance, while paddle leads are
generally placed by a neurosurgeon or an
orthopedic surgeon via an open procedure that would involve a laminotomy
or laminectomy. Prior to implantation,
patients undergo a temporary trial,
usually lasting anywhere from 3 to 10
days. During this trial, the clinician targets
the patient’s pain by inserting the leads
over the appropriate level of the spinal
cord. The leads are connected to an
external battery back wrapped securely
to the patient. The patient then monitors
pain relief with usual daily activities and
documents this in a diary. At the completion of the trial, the leads are removed in
the office and both the clinician and the
patient will discuss the patient’s response
to the SCS. A successful trial is determined if >50% reduction in baseline pain
is achieved. It is important that the patient
establish realistic goals and expectations
prior to the SCS trial and is satisfied with
the results of trial prior to proceeding with
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a permanent implantation. SCS is a relatively safe procedure and reversible with
implant removal. Adverse events were
reported between 34% and 38% (Song et
al, 2014). The most commonly reported
complication was lead migration and/or
breakage.
Published studies have shown that when
used by properly selected patients, SCS
therapy is successful in managing chronic
pain. Kumar et al. (2008) found that in
selected patients with FBSS, treatment
with SCS results in pain relief sustained at
24 months and is associated with patient

satisfaction and clinically significant gains
in functional capacity and quality of life.
The advancements in SCS have led to
more patient-friendly options that do
not allow the therapy to interfere with a
patient’s function but will allow for more
flexibility. Earlier introduction of SCS in
the pain management algorithm that
focuses on individualized pain therapy
can lead to better long-term outcomes
for the patient. Ultimately, patients should
be well-informed of the available options
that would best suit his or her needs.
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